• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Creabilis begins phase IIb trial of CT327 in psoriasis

Creabilis begins phase IIb trial of CT327 in psoriasis

March 14, 2012
CenterWatch Staff

Creabilis, a European biotechnology company specializing in dermatology, inflammation and pain, has initiated a phase IIb global clinical trial of its lead product CT327 in patients with psoriasis vulgaris.

The phase IIb study is a randomized, double-blind, placebo controlled dose finding study of the efficacy and safety of a new CT327 ointment formulation (0.05%, 0.1% and 0.5% w/w) administered for up to eight weeks in patients with psoriasis. A total of 160 patients are expected to complete the trial and results are anticipated towards the end of 2012.

CT327 is a novel topically applied TrkA kinase inhibitor developed using Creabilis' low systemic exposure (LSE) technology. LSE technology creates new chemical entities which allow high local concentrations combined with low systemic exposure; these are ideal characteristics for medicines designed for topical applications.

Results from Creabilis’ phase IIa study of CT327 in psoriasis, released in March 2011, showed that CT327 (0.1% w/w cream formulation) produced a good efficacy response across multiple endpoints including physician global assessment and mPASI (modified Psoriasis Area and Severity Index). CT327 was also well tolerated with no reported application site irritation. Pharmacokinetic analysis showed no detectable plasma CT327, as anticipated with the LSE technology.

"Our phase IIb trial of CT327 is another important step in the development of a product that we believe has exciting potential in the treatment of psoriasis and other important skin diseases,” said Dr. David Roblin, chief medical officer of Creabilis. “This study uses the new and proposed commercial ointment formulation and in three concentrations of CT327 to ensure that the best dose is selected for phase III start. We look forward to building on the very promising phase IIa results already generated."

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing